Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease

https://doi.org/10.1016/j.nbd.2020.104846Get rights and content
Under a Creative Commons license
open access

Highlights

  • Intracerebroventricular administration of A-dopamine is feasible in MPTP monkey.

  • No tachyphylaxia with circadian anaerobic administration by programmable pump.

  • Administration of A-dopamine improves dopa-responsive motor symptoms.

  • No dyskinesia under continuous central A-dopamine conversely to peripheral L-dopa.

  • Safe therapeutic index with intracerebroventricular administration of A-dopamine.

Abstract

Background

Continuous compensation of dopamine represents an ideal symptomatic treatment for Parkinson's disease (PD). The feasibility in intracerebroventricular administration (i.c.v.) of dopamine previously failed because of unresolved dopamine oxidation.

Objectives

We aim to test the feasibility, safety margins and efficacy of continuous i.c.v. of anaerobic-dopamine (A-dopamine) with a pilot translational study in a non-human primate model of PD.

Methods

Continuous and circadian i.c.v. of A-dopamine was administered through a micro-pump connected to a subcutaneous catheter implanted into the right frontal horn of 8 non-human primates treated with 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP). A-dopamine was assessed at acute doses previously reported for dopamine as well as evaluating the long term therapeutic index of A-dopamine in comparison to anaerobically prepared L-dopa or methyl ester L-dopa.

Results

Over 60 days of a continuous circadian i.c.v. of A-dopamine improved motor symptoms (therapeutic index from 30 to 70 mg/day) without tachyphylaxia. No dyskinesia was observed even with very high doses. Death after 1 to 10 days (without neuronal alteration) was only observed with doses in excess of 160 mg whereas L-dopa i.c.v. was not effective at any dose. The technical feasibility of the administration regimen was confirmed for an anaerobic preparation of dopamine and for administration of a minimal infusion volume by micro-pump at a constant flow that prevented obstruction.

Conclusion

Continuous circadian i.c.v. of A-dopamine appears to be feasible and shows efficacy without dyskinesia with a safe therapeutic index.

Keywords

Parkinson's disease
Dopamine in anaerobia
Continuous dopaminergic stimulation
Motor fluctuations with dyskinesia
Neurosurgical treatment

Cited by (0)